Balt International announced that it has received CE mark for the Squidperi 34 and 34LD liquid embolic agents.
Squidperi is a non-adhesive liquid embolic agent indicated for peripheral embolization. It is composed of ethylene vinyl alcohol copolymer (EVOH) dissolved in dimethyl sulphoxide (DMSO) and with (suspended) micronised tantalum powder for radiopacity.
“We are excited to provide physicians with the ability to widen their treatment options with Squidperi 34 and 34LD. The unique lighter tantalum and more fluid versions offered by Balt in our liquid embolic product portfolio represent significant advances in embolization treatment solutions,” said Nicolas Plowiecki, president of Balt.
“Balt is now able to offer one of the largest portfolio for peripheral solutions, including EVOH liquid embolic agents, embolic coil systems and patented dual lumen balloon devices. Balt will continue to support the peripheral embolization field by adapting innovative solutions in our product portfolio to create clinically significant advancements for the peripheral embolization field,” commented Pascal Girin, CEO of Balt and president of Balt International.
Since it was established in 1977, Balt has worked with neurointerventionalists to treat complex life-threatening conditions such as strokes, aneurysms and arteriovenous malformations. It designs manufactures and distributes the interventional neuroradiology devices such as catheters, stents and coils that are essential in treating such conditions. The company is now entering into the interventional radiology space with a comprehensive portfolio around embolization solutions with liquid embolic agent and coils.
